Hello, Fool! | Login | Signup | My Fool
Dec 4, 2008 8:57 PM ET | Feedback | Site Changes | Help
The Company designs, manufactures, sells and services advanced equipment and software products for treating cancer with radiation.
View All Commentary (VAR)
Recs
Manifest (63.44) Submitted: 5/31/07 12:39 PM : Start Price: $40.08 VAR Score: 37.68
Varian reported slightly weaker results and moderated expectations going forward and the price got fried. This cancer-treatment supplier isn't slowing a great deal from 15% annualized top line growth -- just a smidge. S&P rates VAR at 91% of fair value and Morningstar is at 77%. Our projected annual return (PAR) is 18% with an excellent quality rating. The recent price action suggests that VAR is potentially over-sold.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.